Details

Impact of regulatory risk communication on thrombosis with thrombocytopenia syndrome for COVID-19 adenovirus vector vaccines on European Healthcare Professionals
ID Vliet, Ella van (Author), ID Čebron Lipovec, Nanča (Author), ID van der Goot, Marloes (Author), ID Abtahi, Shahab (Author), ID Ribeiro-Vaz, Inês (Author), ID Poplavska, Elita (Author), ID Dermiki-Gkana, Foteini (Author), ID Oikonomou, Chara (Author), ID Deligianni, Elena (Author), ID Kos, Mitja (Author)

.pdfPDF - Presentation file, Download (386,89 KB)
MD5: 752E2F82E042EEABCC6CCDD8273CF56D
URLURL - Source URL, Visit https://onlinelibrary.wiley.com/doi/10.1002/pds.70057 This link opens in a new window

Abstract
Purpose: The European Medicines Agency (EMA) issued regulatory actions and communications in 2021 on thrombosis withthrombocytopenia syndrome (TTS) associated with adenovirus vector vaccines Vaxzevria or Jcovden. This study aimed to eval-uate the impact of these actions on awareness, knowledge and implementation in practises of healthcare professionals (HCP).Methods: Web-based cross-sectional surveys were conducted on HCPs engaged in the vaccination, monitoring or counsellingabout the vaccines. We measured awareness and knowledge of the risk of TTS and their implementation of recommendationsin practise. Descriptive and qualitative analyses were conducted. This study took place in Greece, Latvia, Netherlands, Portugaland Slovenia. Results: We surveyed 1659 HCPs. From these, 914 were included in the analysis. Most were aware about the reports of TTSassociated with COVID-19 adenovirus vector vaccines, with countries reporting percentages between 85% and 97%. Mainstreammedia, health authorities and peers were the main sources of TTS risk information. Most HCPs were able to identify key symptoms from TTS but were less familiar with minor symptoms. Guidelines from health authorities on COVID-19 vaccinationimpacted on professional practise of 55%–77% of HCPs. The reported use of product information across countries was moderate,with some variations. Conclusions: Awareness about and knowledge of TTS risk from COVID-19 adenoviral vector vaccines were high among HCPs.HCPs reported a clear preference for national guidelines as source of risk information and the implementation of product infor-mation remained moderate across countries.

Language:English
Keywords:COVID-19 vaccines, healthcare professionals, regulatory actions, risk communication, SARS- CoV-2 adenovirus vector vaccines, thrombosis with thrombocytopenia syndrome
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2024
Number of pages:14 str.
Numbering:Vol. 33, iss. 12, [article e70057]
PID:20.500.12556/RUL-165843 This link opens in a new window
UDC:615.371:616-005.6
ISSN on article:1053-8569
DOI:10.1002/pds.70057 This link opens in a new window
COBISS.SI-ID:216692483 This link opens in a new window
Publication date in RUL:12.12.2024
Views:682
Downloads:94
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Pharmacoepidemiology and drug safety
Shortened title:Pharmacoepidemiol. drug saf.
Publisher:Wiley
ISSN:1053-8569
COBISS.SI-ID:1515540 This link opens in a new window

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.

Secondary language

Language:Slovenian
Keywords:regulativni ukrepi, zdravstveni delavci, tromboza s trombocitopeničnim sindromom, tromboza, cepiva, SARS-CoV-2, COVID-19

Projects

Funder:Other - Other funder or multiple funders
Project number:EMA/2018/23/PE
Name:European Medicines Agency
Acronym:EMA

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back